<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05052086</url>
  </required_header>
  <id_info>
    <org_study_id>MAMORECT</org_study_id>
    <nct_id>NCT05052086</nct_id>
  </id_info>
  <brief_title>Magnetomotoric Ultrasound (MMUS) in Rectal Cancer</brief_title>
  <acronym>MAMORECT</acronym>
  <official_title>Magnetomotoric Ultrasound (MMUS) in the Staging of Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region Skane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Region Skane</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Magnetomotoric ultrasound, combines conventional ultrasound with a time-varying magnetic&#xD;
      field. The aim is to improve diagnosis of mesolectal lymph nodes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Magnetomotoric ultrasound, combines conventional ultrasound with a time-varying magnetic&#xD;
      field. Nanoparticles are injected close to the rectal cancer and migrate to adjacent lymph&#xD;
      nodes.The time-varying magnetic field will influence the nano particles in the lymph node&#xD;
      enhancing diagnosis of affected lymph nodes. The aim is to improve diagnosis of mesolectal&#xD;
      lymph nodes and compare the results of magnetomotoric ultrasound with MRI and final&#xD;
      histopathology.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Included patients will undergo magnetomotoric ultrasound in addition to conventional MRI. The results of MRI examination and magnetomotoric ultrasound will be compared with final histopathology.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Accuracy of mesorectal lymph node diagnosis with MMUS, compared with final histopathology</measure>
    <time_frame>Approximately 1 hour after MMUS</time_frame>
    <description>Evaluation of the accuracy of MMUS in detecting lymph node metastases in rectal cancer. The results of the MMUS (malignant or benign lymph nodes) will be compared with final histopathology. The accuracy will be expressed in sensitivity (%), specificity (%) and overall accuracy (% correctly staged lymph nodes with MMUS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Accuracy of mesorectal lymph node diagnosis with MMUS, compared with preoperative MRI</measure>
    <time_frame>Approximately 1 hour after MMUS</time_frame>
    <description>Evaluation of the accuracy of MMUS in detecting lymph node metastases in rectal cancer in comparison to standard staging (MRI). The results of the MMUS (malignant nodes or benign nodes) will be compared with the results of preoperative MRI (malignant or benign lymph nodes) and the final histopathology. The accuracy will be expressed in sensitivity (%), specificity (%) and overall accuracy (% correctly staged lymph nodes) with MMUS and MRI.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Magnetomotoric ultrasound</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Magnetomotoric ultrasound in addition to MRI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Magnetomotoric ultrasound</intervention_name>
    <description>Nanoparticles will be injected close to the tumor. Magnetomotoric ultrasound will be performed just before scheduled standard operation, when the patient is anesthetized.</description>
    <arm_group_label>Magnetomotoric ultrasound</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Rectal cancer&#xD;
&#xD;
          -  Scheduled for total mesorectal surgery&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not able to give informed consent&#xD;
&#xD;
          -  Synchronus colorectal cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carl-Fredrik Rönnow, MD, PhD</last_name>
    <phone>+4640-331635</phone>
    <email>carl-fredrik.ronnow@med.lu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Henrik Thorlacius, Professor</last_name>
    <phone>+46 40-331000</phone>
    <email>henrik.thorlacius@med.lu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Skane University Hospital, Malmö, section of Surgery</name>
      <address>
        <city>Malmö</city>
        <state>Skåne</state>
        <zip>20501</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carl-Fredrik Rönnow, MD, PhD</last_name>
      <phone>+46 40-331635</phone>
      <email>carl-fredrik.ronnow@med.lu.se</email>
    </contact>
    <contact_backup>
      <last_name>Henrik Thorlacius, Professor</last_name>
      <phone>+46 40-331000</phone>
      <email>henrik.thorlacius@med.lu.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 6, 2021</study_first_submitted>
  <study_first_submitted_qc>September 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

